24/7 Market News Snapshot 09 October, 2024 – Clearside Biomedical, Inc. Common Stock (NASDAQ:CLSD)

October 9, 2024

DENVER, Colo., 09 October, 2024 (247marketnews.com) – (NASDAQ:CLSD) are discussed in this article.
Clearside Biomedical, Inc. is currently experiencing significant bullish momentum, trading at $1.856, which represents a notable gain of 25.41% from its previous close of $1.480. This surge is accompanied by an impressive pre-market trading volume of approximately 1.09 million shares, indicating heightened investor interest and confidence in the company. This upward trend may be attributed to recent developments, particularly the positive results from the ODYSSEY Phase 2b clinical trial of CLS-AX, an injectable suspension of axitinib intended for the treatment of neovascular age-related macular degeneration (wet AMD).

The ODYSSEY trial has revealed promising outcomes, demonstrating CLS-AX’s efficacy in maintaining stable visual acuity and anatomical control over a 36-week period. Remarkably, around 67% of participants did not require additional treatments after six months, resulting in an 84% reduction in treatment burden compared to current therapies. These results highlight the potential of the suprachoroidal delivery method as a transformative option for patients facing the challenges of frequent injections.

George Lasezkay, President and CEO of Clearside, expressed optimism regarding the topline data, emphasizing both the therapeutic efficacy and safety profile of CLS-AX, with no serious treatment-related adverse events reported. He articulated confidence in advancing the CLS-AX program into Phase 3 development, recognizing it as a pivotal achievement in delivering effective, long-acting treatment options for wet AMD patients.

Further analysis from the trial indicated that CLS-AX effectively maintained stable best corrected visual acuity and central subfield retinal thickness, reinforcing its position as a competitive player in the landscape of wet AMD treatments. Chief Medical Officer Victor Chong noted that the trial confirmed CLS-AX’s potential to offer differentiated dosing flexibility, establishing it as a viable alternative in retinal disease therapies.

As Clearside continues to evaluate these groundbreaking findings, the company is committed to presenting additional data at upcoming medical meetings, furthering its mission to innovate within ocular therapeutics and ultimately enhance the quality of life for individuals living with wet AMD.

Related news for (CLSD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.